Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.48 |
| ▸ | TNKS | O95271 | 2/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.46 |
| ▸ | HTR1A | P08908 | 9/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22808957 | 0.80 | IDO1 (0.48) | HTR6NR1I2IDO1CDK9 | |
| SCHEMBL7964040 | 0.78 | IDO1 (0.56) | HTR6SLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL22809064 | 0.77 | IDO1 (0.42) | NR1I2IDO1CDK9 | |
| SCHEMBL21138095 | 0.75 | HTR6 (0.49) | HTR6SLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL19284552 | 0.75 | HTR1A (0.54) | SLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL21138081 | 0.74 | IDO1 (0.52) | HTR6IDO1 | |
| SCHEMBL18806755 | 0.70 | IDO1 (0.44) | NR1I2IDO1 | |
| SCHEMBL17762857 | 0.70 | IDO1 (0.44) | NR1I2IDO1 | |
| SCHEMBL30232333 | 0.70 | SLC6A2 (0.55) | HTR6SLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL187795 | 0.70 | SLC6A2 (0.55) | HTR6SLC6A2SLC6A4HTR1ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2020-11-12 | — | — | US | disclosed |
| WO-2019115586-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | HTR6 808/4885TNKS 1347/4885TNKS2 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.